Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 27 (1), 87-88

The Benefit-Risk Consideration in Long-Term Use of Alternate-Day, Low Dose Aspirin: Focus on Colorectal Cancer Prevention

Affiliations

The Benefit-Risk Consideration in Long-Term Use of Alternate-Day, Low Dose Aspirin: Focus on Colorectal Cancer Prevention

Seong Eun Kim. Ann Gastroenterol.

Conflict of interest statement

Conflict of Interest: None

Similar articles

See all similar articles

References

    1. Cuzick J, Otto F, Baron JA, et al. Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. Lancet Oncol. 2009;10:501–507. - PubMed
    1. Rothwell PM, Wilson M, Elwin CE, et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet. 2010;376:1741–1750. - PubMed
    1. Flossmann E, Rothwell PM. British Doctors Aspirin Trial and the UK-TIA Aspirin Trial. Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet. 2007;369:1603–1613. - PubMed
    1. Cook NR, Lee IM, Gaziano JM, et al. Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial. JAMA. 2005;294:47–55. - PubMed
    1. Cook NR, Lee IM, Zhang SM, Moorthy V, Buring JE. Alternate-day, low-dose aspirin and cancer risk: long-term observational follow-up of a randomized trial. Ann Intern Med. 2013;159:77–85. - PMC - PubMed

LinkOut - more resources

Feedback